Comparative Pharmacology
Head-to-head clinical analysis: DDAVP NEEDS NO REFRIGERATION versus STIMATE NEEDS NO REFRIGERATION.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DDAVP NEEDS NO REFRIGERATION versus STIMATE NEEDS NO REFRIGERATION.
DDAVP (NEEDS NO REFRIGERATION) vs STIMATE (NEEDS NO REFRIGERATION)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desmopressin is a synthetic analogue of vasopressin (antidiuretic hormone) that acts on V2 receptors in renal collecting ducts to increase water reabsorption and concentrate urine. It also raises plasma levels of factor VIII and von Willebrand factor via V2 receptor activation on endothelial cells.
Desmopressin is a synthetic analogue of vasopressin (antidiuretic hormone) that increases cyclic AMP levels in renal collecting duct cells, enhancing water reabsorption and concentrating urine. It also raises plasma levels of von Willebrand factor and factor VIII by stimulating release from endothelial stores.
1-2 mg orally twice daily for central diabetes insipidus; intranasal 10-40 mcg/day in 1-3 divided doses; IV/SC 0.5-2 mcg/day in divided doses for diabetes insipidus.
Intranasal: 1 spray (1.5 mg) into one nostril; may repeat once after 30-60 minutes if needed. Not to exceed 2 doses per bleeding episode.
None Documented
None Documented
Terminal elimination half-life is 1.5-3 hours for intravenous and oral routes; increased to 3-5 hours in patients with renal impairment.
Terminal elimination half-life is 2-4 hours (mean 3 hours), which supports a dosing interval of 2-4 hours in clinical use.
Primarily renal (approximately 60-70% excreted unchanged in urine); minimal biliary/fecal elimination (<5%).
Renal excretion of intact drug and metabolites accounts for >90% of elimination; biliary/fecal excretion is minimal (<5%).
Category C
Category C
Antidiuretic Hormone Analog
Antidiuretic Hormone Analog